Virbac stock heads into the open after a 1.95% drop on Euronext Paris

At the close on September 10, 2026, Virbac stock finished at EUR 302.00 on Euronext Paris, down 1.95% with a day range between EUR 300.50 and EUR 308.50. The move came as European equities eased after the ECB rate hike, with Paris slipping around 0.5%.

Virbac stock closed at EUR 302.00 on Euronext Paris on September 10, 2026, marking a 1.95% decline from the previous session and extending its recent pullback. The shares moved between EUR 300.50 and EUR 308.50 during the session, reflecting continued volatility in European mid-cap names.

September 10, 2026 in numbers

Virbac SA (ISIN FR0000031577) ended the September 10, 2026 session on Euronext Paris at EUR 302.00, down 1.95% from the prior close, after opening at EUR 308.50 and trading in a range between EUR 300.50 and EUR 308.50 according to Euronext Paris data. The closing level placed the stock modestly above recent lows seen earlier in the week, but still below the EUR 313.50 close recorded on September 9, 2026, when it slipped 1.26% in that session per an equity wrap from Ad-hoc-news. Trading volumes stayed within a typical range for the stock, while the broader CAC All Shares index also came under pressure, with Paris benchmarks losing about 0.5% after the latest European Central Bank rate hike, as noted by Tribuna do Sertao. Against that backdrop, Virbac stock underperformed the broad Paris market but remained within its established 52-week trading corridor.

Today's backdrop for Virbac stock

Looking ahead to today's session on September 11, 2026, Virbac faces a market environment still shaped by the ECB's recent decision to raise interest rates, which weighed on European equities and particularly on indices such as the CAC 40, as covered by La Gazzetta del Mezzogiorno. In parallel, Virbac has been in the news for its Every Pet Project charity initiative, which calls on veterinary professionals and pet owners to nominate animal welfare organizations for recognition, a program highlighted in a recent release from PR Newswire. While the charity program is not directly market-moving, it keeps the company's brand visible as investors digest the latest rate decisions and reassess valuations across the European healthcare and animal health segments heading into today's trading.